Bioactivity, pharmacokinetics, and immunogenicity assays in preclinical and clinical trials for recombinant human endostatin

Acta Pharmacologica Sinica

Volumn 29, Issue 11, 2008, Pages 1357-1369

  Hu, Bi ^a   Zhu, Hao Wen ^b   Zhu, Li Ping ^a   Li, Chen ^a   Rong, Zhi Gang ^b   Xu, Jia Ming ^b   Wu, Zhi Wei ^a   Wang, Jian Jun ^a   Xu, Gen Xing ^a,b  

^a NANJING UNIVERSITY   (China)

^b Jiangsu Research Center for Gene Pharmaceutical Engineering and Technology   (China)

Author keywords

Bioactivity; Immunogenicity; Pharmacokinetics; Recombinant human endostatin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ENDOSTATIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LACTATE DEHYDROGENASE; RECOMBINANT ENDOSTATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL PROLIFERATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; ENDOTHELIUM CELL; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOGENICITY; LIVER TUMOR; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RHESUS MONKEY; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ENDOSTATINS; ENDOTHELIAL CELLS; FEMALE; HUMANS; MACACA MULATTA; MALE; MICE; RECOMBINANT PROTEINS; SEX CHARACTERISTICS; TETRAZOLIUM SALTS; THIAZOLES;

EID: 55149107664     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00865.x     Document Type: Article

References (39)

1. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997 88 : 277 85.
2. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000 486 : 247 51.
3. Zhang P, Wu D, Ge J, Zhu Z, Feng G, Yue T, et al. Experimental inhibition of corneal neovascularization by endostatin gene transfec-tion in vivo. Chin Med J (Engl) 2003 116 : 1869 74.
4. Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, Iruela-Arispe ML, et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 1999 59 : 189 97.
5. Bloch W, Huggel K, Sasaki T, Grose R, Bugnon P, Addicks K, et al. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J 2000 14 : 2373 6.
6. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997 390 : 404 7.
7. Yin G, Liu W, An P, Li P, Ding I, Planelles V, et al. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol Ther 2002 5 : 547 54.
8. Pia N, Pia H, Timo S, Jani L, Ritva H, Ulf-Hakan S, et al. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem 2003 278 : 22 404 11.
9. Skovseth DK, Veuger MJ, Sorensen DR, Angelis PM, Haraldsen G. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood 2005 105 : 1044 51.
10. Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, et al. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 2004 10 : 33 42.
11. Sorensen DR, Read TA, Porwol T, Olsen BR, Timpl R, Sasaki T, et al. Endostatin reduces vascularization, blood flow, and growth in a rat gliosarcoma. Neurooncol 2002 4 : 1 8.
12. Park JH, Chang KH, Lee JM, Lee YH, Chung IS. Optimal production an in vitro activity of recombinant endostatin from stably transformed Drosophila melanogaster S2 cells. In Vitro Cell Dev Biol Anim 2001 37 : 5 9.
13. Sim BK, MacDonald NJ, Gubish ER. Angiostatin and endostatin: Endogenous inhibitors of tumor growth. Cancer Metastasis Rev 2000 19 : 181 90.
14. Huang XJ, Wong MK, Zhao Q, Zhu ZY, Wang KZ, Huang N, et al. Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect. Cancer Res 2001 61 : 478 81.
15. Sim BK, Fogler WE, Zhou XH, Liang H, Madsen JW, Luu K, et al. Zinc ligand-disrupted recombinant human endostatin: Potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 1999 3 : 41 51.
16. Song HF, Liu XW, Zhang HN, Zhu BZ, Yuan SJ, Liu SY, et al. Pharmacokinetics of His-tag recombinant human endostatin in rhesus monkeys. Acta Pharmacol Sin 2005 26 : 124 8.
17. Wang JW, Sun Y, Liu YY, Yu QT, Zhang QP, Li K, et al. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chi J Lung Cancer 2005 8 : 283 90.
18. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006 24 : 3555 61.
19. Bachelot T, Ratel D, Menetrier-Caux C, Wion D, Blay JY, Berger F. Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. Br J Cancer 2006 94 : 1066 70.
20. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002 20 : 3804 14.
21. Hansma AHG, Broxterman HJ, van der Horst I, Yuana Y, Boven E, Giaccone G, et al. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Ann Onc 2005 16 : 1695 701.
22. Eder JP, Supko JG Jr., Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002 20 : 3772 84.
23. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002 20 : 3792 803.
24. Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003 21 : 223 31.
25. Yang L, Wang JW, Tang ZM, Liu XW, Huang J, Li ST, et al. A phase I clinical trial for recombinant human endostatin. Chin J New Drugs 2004 13 : 548 53.
26. Zhang HY, Han QW, Xu YF, Fan YR, Dai QM, Xu JM, et al. The methods for determining the purity and in vitro or in vivo activity of recombinant human endostatin. Cancer Biol Ther 2005 4 : 207 12.
27. The State Pharmacopoeia Committee of the People's Republic of China. Pharmacopoeia of the People's Republic of China, part III, 2005 ed. Beijing : Chemical Industry Press 2005.
28. Lee Sim BK, O'Reilly MS, Liang H, Fortier AH, He WX, Madsen JW, et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 1997 57 : 1329 34.
29. Xu YF, Zhu LP, Hu B, Rong ZG, Zhu HW, Xu JM, et al. A quantitative method for assessing the antitumor potency of human recombinant endostatin. Eur J Pharmacol 2007 564 : 1 6.
30. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000 6 : 1160 6.
31. Tong ZS, Yan Z, Ba Y, Li SF, Shi YH, He LH, et al. Phase I clinical study of recombinant human endostatin. J Chin Modern Med 2006 3 : 1150 5.
32. Sasaki T, Fukai N, Mann K, Gohring W, Olsen BR, Timpl R. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J 1998 17 : 4249 56.
33. Abdollahi A, Hlatky L, Huher P. Endostatin: the logic of anti-angiogenic therapy. Drug Resist Updat 2005 8 : 59 74.
34. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999 18 : 4414 23.
35. Jung SP, Siegrist B, Hornick CA, Wang YZ, Wade MR, Anthony CT, et al. Effect of human recombinant endostatin protein on human angiogenesis. Angiogenesis 2002 5 : 111 8.
36. Wang YS, Eichler W, Friedrichs U, Yafai Y, Hoffmann S, Yasukawa T, et al. Impact of endostatin on bFGF-induced proliferation, migration, and matrix metalloproteinase-2 expression/secretion of bovine choroidal endothelial cells. Curr Eye Res 2005 30 : 479 89.
37. McCarty MF, Baker CH, Bucana CD, Fidler IJ. Quantitative and qualitative in vivo angiogenesis assay. Int J Oncol 2002 21 : 5 10.
38. Li Q, Olsen BR. Increased angiogenic response in aortic explants of collagen XVIII/endostatin-null mice. Am J Pathol 2004 165 : 415 24.
39. Lee TY, Tjin Tham Sjin RM, Movahedi S, Ahmed B, Pravda EA, Lo KM, et al. Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy. Clin Cancer Res 2008 14 : 1487 93.